Selectikine comprises the monoclonal antibody (mAb) NHS76, which recognizes single-or double-stranded DNA often released from dying tumor cells either spontaneously or following treatment with radiation or chemotherapy [18,19], and two genetically modified IL-2 molecules, with a D20T mutation aimed at eliminating the toxin motif responsible for endothelial cell binding [15]. Here, IL2 is linked to neoplasm.